MorphoSys AG has received a clinical milestone payment from Centocor Ortho Biotech Inc. for a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases.
Researchers have found that leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes.
A study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival; it also correlates with a worse outcome.
The American Heart Journal reported results of a clinical trial evaluating Amorcyte, Inc.’s lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.
Tekmira Pharmaceuticals Corporation, a developer of RNA interference therapeutics, announced it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1.
Biogen Idec and Elan Corp. said they have applied to U.S. and European regulators to update prescribing information for the multiple sclerosis drug Tysabri to help classify the risk of a rare but serious brain infection.
Ligand Pharmaceuticals Inc. said it will receive a $1 million payment from Pfizer Inc. as part of a partnership for the potential contraceptive Tanaproget.
Two pharmaceutical companies have agreed to a settlement with two Nevada women who claimed hormone replacement drugs caused their breast cancer.
Teva Pharmaceutical Industries Ltd. said it will start selling a generic version of the diabetes drug Actos after settling a patent infringement lawsuit brought by the company that makes Actos, Takeda Pharmaceutical Co.
Vertex Pharmaceuticals Inc. said it stopped part of a midstage clinical study evaluating a combination of two hepatitis C drugs. The company said the combination of telaprevir and VX-222 was not working.
Cumberland Pharmaceuticals Inc. said the Food and Drug Administration rejected the company's request to expand approval for the liver failure drug Acetadote.
Arena Pharmaceuticals Inc. said it plans to again ask the Food and Drug Administration to approve its experimental weight-loss drug lorcaserin by the end of 2011, following the agency's recent rejection over safety concerns.
SAFC announced an extension to Sigma-Aldrich's proprietary CompoZr Zinc Finger Nuclease platform that will expand ZFN-based technology to include off-the-shelf ZFNs and custom cell engineering services for use in the biopharmaceutical industry.
The NI (Non-Interfering) Protein Assay is a highly sensitive colorimetric protein assay that overcomes interference of common laboratory agents present in protein solutions.
Taiho Pharmaceutical Co., Ltd. announced that the Committee for Medicinal Products for Human Use has recommended approval of Teysuno, a novel oral anti-cancer agent, for treatment in adults with advanced gastric cancer when given in combination with cisplatin.